Systematic optimization of host-directed therapeutic targets and preclinical validation of repositioned antiviral drugs.

ABSTRACT: Inhibition of host protein functions using established drugs produces a promising antiviral effect with excellent safety profiles, decreased incidence of resistant variants and favorable balance of costs and risks. Genomic methods have produced a large number of robust host factors, providing candidates for identification of antiviral drug targets. However, there is a lack of global perspectives and systematic prioritization of known virus-targeted host proteins (VTHPs) and drug targets. There is also a need for host-directed repositioned antivirals. Here, we integrated 6140 VTHPs and grouped viral infection modes from a new perspective of enriched pathways of VTHPs. Clarifying the superiority of nonessential membrane and hub VTHPs as potential ideal targets for repositioned antivirals, we

SUBMITTER: Xie D 

PROVIDER: S-EPMC9116211 | biostudies-literature | 2022 May

REPOSITORIES: biostudies-literature